NCT06945068View on ClinicalTrials.gov

An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

November 30, 2026

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
BIOLOGICAL

GB261

GB261 will be dosed according to the assigned group.

Trial Locations (1)

430000

Wuhan Union Hospital, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER